Načítá se...
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...
Uloženo v:
| Vydáno v: | Transl Psychiatry |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026402/ https://ncbi.nlm.nih.gov/pubmed/32066688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41398-020-0709-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|